Group 1 - The company received a resignation letter from non-independent director Chen Yungui due to internal work adjustments, but she will continue to serve as the deputy general manager [1] - Chen Yungui's resignation will not reduce the board members below the legal minimum, and her resignation is effective upon delivery [1] Group 2 - The company held the first temporary employee representative meeting on August 18, 2025, to elect Shu Jie as the employee director of the fifth board, with a term from August 18, 2025, to August 23, 2026 [2] - Shu Jie meets the qualifications and conditions for the position as per the Company Law and the company's articles of association, and the number of employee representatives on the board does not exceed half of the total board members [2] Group 3 - Shu Jie, born in 1977, graduated from South China University of Technology with a degree in polymer materials and engineering, and has held various positions within the company since 2011 [4] - As of now, Shu Jie does not hold any shares in the company and has no relationship with the actual controller or major shareholders, and has not faced any penalties from the China Securities Regulatory Commission or other relevant authorities [4]

Group 1 - The latest stock price of the company is 14.83 yuan, with an increase of 0.01 yuan compared to the previous trading day. The intraday high reached 14.94 yuan, and the low dipped to 14.68 yuan, with a total trading volume of 1.07 billion yuan [1] - The company operates in the medical device industry, focusing on the research, production, and sales of medical catheters and other medical devices. Its product range includes anesthesia, urology, respiratory, and hemodialysis fields [1] - The latest announcement indicates that non-independent director Chen Yungui has resigned from the board due to work adjustments but will retain the position of deputy general manager. Additionally, Shu Jie has been elected as the employee director of the company's fifth board of directors [1] Group 2 - On the day of the report, the main capital flow showed a net outflow of 4.0961 million yuan, with a cumulative net outflow of 10.5962 million yuan over the past five trading days [1]

Core Points - Weili Medical (603309) announced the resignation of non-independent director Chen Yungui due to internal work adjustments, while she will continue to serve as the company's deputy general manager [1] - The company will hold its first temporary employee representative meeting on August 18, 2025, to elect Shu Jie as the employee director of the fifth board of directors [1]

Group 1 - The company announced the resignation of non-independent director Chen Yungui due to internal work adjustments, while she will continue to serve as the deputy general manager [1] - The company held its first temporary employee representative meeting on August 18, 2025, where Shu Jie was elected as the employee director of the fifth board of directors, with a term from August 18, 2025, to August 23, 2026 [1] - Shu Jie meets the qualifications and conditions for serving as an employee director as per the Company Law and the company's articles of association, and his election maintains compliance with legal requirements regarding board composition [1][2] Group 2 - Shu Jie, born in 1977, graduated from South China University of Technology with a degree in polymer materials and engineering, and has held various positions within the company since 2011 [2] - His previous roles include manager of the R&D department, supervisor, and assistant director of the research institute, and he has no shareholding in the company or any related party relationships with the actual controller or major shareholders [2] - Shu Jie has not faced any penalties from the China Securities Regulatory Commission or other relevant authorities, confirming his eligibility to serve as a director of a listed company [2]

证券代码：603309 证券简称：维力医疗 公告编号：2025-054 广州维力医疗器械股份有限公司 关于公司非独立董事辞职暨选举职工董事的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 董事会 2025 年 8 月 19 日 附：舒杰先生简历 舒杰：男，1977 年出生，中国国籍，华南理工大学高分子材料与工程专业本科 毕业。 主要工作经历：2011 年至 2019 年任广州维力医疗器械股份有限公司研发部经 理，2015 年 9 月至 2025 年 8 月 15 日任广州维力医疗器械股份有限公司监事，2020 年 1 月至今任广州维力医疗器械股份有限公司研究院院长助理兼研发总监，2025 年 8 月 18 日起任广州维力医疗器械股份有限公司职工董事。 截至目前，舒杰先生未持有公司股份，与公司实际控制人、控股股东之间不存 在关联关系，未曾受到中国证监会及其他有关部门的处罚和证券交易所惩戒，符合 《公司法》《公司章程》规定的担任上市公司董事的条件。 广州维力医疗器械股份有限公司（以下简称"公司"）于近日收到公司非独立 董事陈 ...

Group 1 - The core point of the article is the resignation of non-independent director Chen Yungui from the board of Guangzhou Weili Medical Equipment Co., Ltd due to internal work adjustments, while she will continue to serve as the deputy general manager [1] Group 2 - The resignation report became effective upon delivery [1]

Summary of Key Points Core Viewpoint - Vili Medical (603309) has shown a positive stock performance, with a recent closing price of 14.82 yuan, reflecting a 2.28% increase from the previous week, and reaching a near one-year high of 15.44 yuan on August 12, 2025 [1]. Company Announcements - Vili Medical is participating in the establishment of the Vizhih Medical Industry Investment Partnership, aiming to raise 150 million yuan, with Vili Medical committing 37.5 million yuan, representing 25% of the total investment [1]. - The company has revised its Independent Director Work System to enhance corporate governance and ensure the protection of minority shareholders' rights, detailing the roles and qualifications of independent directors [1].

广州维力医疗器械股份有限公司 股东会议事规则 广州维力医疗器械股份有限公司 股东会议事规则 第一章 总 则 第一条 为促进广州维力医疗器械股份有限公司（以下简称"公司"）规范 运作，提高股东会议事效率，保障股东合法权益，保证大会程序及决议内容的合 法有效性，根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中 华人民共和国证券法》（以下简称"《证券法》"）、《上市公司股东会规则》、 《广州维力医疗器械股份有限公司章程》 （以下简称"公司章程"）等有关规定， 结合公司实际情况，制订本议事规则。 第二条 公司应当严格按照法律、行政法规、本规则及公司章程的相关规定 召开股东会，保证股东能够依法行使权利。 广州维力医疗器械股份有限公司 股东会议事规则 公司董事会应当切实履行职责，认真、按时组织股东会。公司全体董事应当 勤勉尽责，确保股东会正常召开和依法行使职权。 第三条 股东会应当在《公司法》和公司章程规定的范围内行使职权。 第四条 股东会分为年度股东会和临时股东会。年度股东会每年召开一次， 应当于上一会计年度结束后的六个月内举行。临时股东会不定期召开，出现《公 司法》第一百一十三条规定的应当召开临时股东会的 ...

Meeting Details - The shareholders' meeting was held on August 15, 2025, at the company's office in Guangzhou [1] - The meeting was legally convened and conducted in accordance with the Company Law and the Articles of Association [1][4] Voting Results - All proposed resolutions were approved with significant majority votes, including: - A resolution regarding the limited sale shares received 99.6389% approval from A-shareholders [1] - Subsequent resolutions also received over 99.6% approval from A-shareholders [2][3] - The voting method combined on-site and online voting, ensuring compliance with legal requirements [1] Legal Compliance - The meeting's procedures were verified by lawyers, confirming adherence to the Company Law and relevant regulations [3][4] - The resolutions passed met the necessary thresholds for special and ordinary resolutions as per legal standards [3]

Group 1 - The legal opinion confirms that the convening and holding procedures of the shareholders' meeting comply with the Company Law, Shareholders' Meeting Rules, and the company's articles of association [1][4][5] - The meeting was convened by the company's board of directors, which is qualified to do so [2][3] - A total of 5 shareholders and their proxies attended the meeting in person, representing 146,754,556 shares, which accounts for 50.11% of the total voting shares [3][4] Group 2 - 164 shareholders participated in the online voting, representing 14,468,905 shares, or 4.94% of the total voting shares [3][4] - The voting process combined both on-site and online methods, with results announced immediately after the voting concluded [4] - The legal opinion concludes that the voting procedures were valid and the results were legitimate [4][5]